gip and glp-1 LY3437943, a novel triple glucagon, GIP, receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept Frontiers | Clinical perspectives on

These modify risk and may help decide how strongly to consider GLP-1 therapy for brain protection

The dosing structure below is community-derived from each compound's Phase 2/3 data plus the Valdecantos 2024 preclinical synergy paper

For the assessment of the changes from baseline following GLP-1-based therapies in % FMD and IMT, mean differences with 95% confidence intervals (CI) were calculated between baseline samples and end-of-treatment samples for each study and then an overall effect size was generated

Therapeutic Doses The difference in dosage is because of different health goals

For trips under 24 hours, this approach adequately protects most peptides